Abstract: An active microfluidic droplet generation device includes a droplet generation junction joining at least one continuous phase channel for carrying a ferrofluid, and a dispersed phase channel for carrying a dispersed phase (e.g., aqueous) flow. A miniature electropermanent magnet (EPM) upstream from the junction generates a magnetic field to modulate a flow rate of a ferrofluid in the continuous phase channel so that dispersed phase droplets are generated with volumes actively controlled on-demand and under continuous flow.
Type:
Application
Filed:
September 30, 2016
Publication date:
April 5, 2018
Inventors:
Jose I. Padovani Blanco, Ali Mohamed Ibrahim, Yasser Hussein Anis, Stefanie S. Jeffrey, Roger T. Howe
Abstract: Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.
Type:
Application
Filed:
December 11, 2008
Publication date:
September 3, 2009
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Ronald W. Davis, Stefanie S. Jeffrey, Michael N. Mindrinos, R. Fabian Pease, Ashley Ann Powell, AmirAli Hajhossein Talasaz
Abstract: Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.
Type:
Application
Filed:
October 28, 2011
Publication date:
February 23, 2012
Applicant:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Ronald W. Davis, Stefanie S. Jeffrey, Michael N. Mindrinos, R. Fabian Pease, Ashley Ann Powell, AmirAli Hajhossein Talasaz
Abstract: Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
February 23, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Ronald W. Davis, Stefanie S. Jeffrey, Michael N. Mindrinos, R. Fabian Pease, Ashley Ann Powell, AmirAli Hajhossein Talasaz
Abstract: Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
December 6, 2011
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Ronald W. Davis, Stefanie S. Jeffrey, Michael N. Mindrinos, R. Fabian Pease, Ashley Ann Powell, AmirAli Hajhossein Talasaz
Abstract: Lithium diphenylphosphide solutions in a solvent, e.g., diethoxymethane (DEM), that are more stable than when tetrahydrofuran (THF) is used as a solvent. Methods of producing them are also disclosed.
Abstract: Lithium diphenylphosphide solutions in a solvent, e.g., diethoxymethane (DEM), that are more stable than when tetrahydrofuran (THF) is used as a solvent. Methods of producing them are also disclosed.
Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.
Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
October 13, 2017
Publication date:
February 1, 2018
Inventors:
Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Grant
Filed:
November 12, 2014
Date of Patent:
November 21, 2017
Assignee:
Codexis, Inc.
Inventors:
Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.
Type:
Application
Filed:
March 12, 2010
Publication date:
July 1, 2010
Inventors:
Jeffrey M. Wu, Jue-Chen Liu, Jeannette Chantalat, Ying Sun, Stefanie A. Johnsen, Hanuman B. Jampani
Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
November 12, 2014
Publication date:
May 14, 2015
Inventors:
Nicholas J. Agard, Oscar Alvizo, Melissa Ann Mayo, Stefanie Ng Minor, James Nicholas Riggins, Jeffrey C. Moore
Abstract: Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36 carboxylic acids and C4-C36 dicarboxylic acids, compositions comprising these esters, and to the use of esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C35-carboxylic acids and/or C4-C36-dicarboxylic acids in cosmetic and/or topical pharmaceutical preparations.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 19, 2016
Assignee:
Cognis IP Management GmbH
Inventors:
Markus Dierker, Catherine Weichold, Stefanie Althaus, Lars Zander, Daniela Prinz
Abstract: Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36 carboxylic acids and C4-C36 dicarboxylic acids, compositions comprising these esters, and to the use of esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36-carboxylic acids and/or C4-C36-dicarboxylic acids in cosmetic and/or topical pharmaceutical preparations.
Type:
Grant
Filed:
January 7, 2014
Date of Patent:
April 19, 2016
Assignee:
Cognis IP Management GmbH
Inventors:
Markus Dierker, Catherine Weichold, Stefanie Althaus, Lars Zander, Daniela Prinz
Abstract: The present invention relates to polypeptides transiently activating Ras homolog gene family member A (RhoA) GTPase, polynucleotides encoding said polypeptides and pharmaceutical compositions comprising said polypeptides or said polynucleotides. The present invention further relates to the use of said polypeptides, said polynucleotides or said pharmaceutical compositions for long-term treatment of damage of the peripheral or central nervous system.
Type:
Grant
Filed:
March 31, 2010
Date of Patent:
June 10, 2014
Inventors:
Gudrun Ahnert-Hilger, Gisela Groβe, Fred Hofmann, Ingo Just, Markus Höltje, Stefanie Hülsenbeck
Abstract: A hardener system for epoxy resins comprising i) at least one aromatic dianhydride compound A having a melting point of at least 35° C., ii) at least one monoanhydride compound B having a melting point of not more than 30° C. and iii) at least one catalyst C, is provided. The aromatic dianhydride compound A is dispersed in the hardener system. The present invention further provides for the use of said hardener systems and to processes for hardening epoxy resin systems.
Type:
Application
Filed:
June 25, 2013
Publication date:
January 2, 2014
Applicant:
Evonik Industries AG
Inventors:
Stefanie RINKER, Franz-Albert von ITTER, Bettina BRESSEL, Benjamin WILLY, Manfred NEUMANN, Chris JONES, Jeffrey H. DIMMIT
Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
February 19, 2016
Publication date:
June 16, 2016
Inventors:
Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
Abstract: Methods are provided for making reversible crosslinked polymers. Exemplary methods comprise reacting first and second thermoplastic polymers having non-hindered olefins in the presence of a metathesis catalyst under conditions sufficient to form a crosslinked polymer. In certain embodiments, the methods comprise providing a crosslink promoting additive to improve the strength of the crosslinked polymer. In some embodiments, the methods comprise decrosslinking a crosslinked polymer through a metathesis or an ozonolysis reaction.
Type:
Grant
Filed:
July 17, 2009
Date of Patent:
November 25, 2014
Assignee:
Tyco Electronics Corporation
Inventors:
Mark W. Ellsworth, Stefanie M. Gravano-Doerffler
Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
October 20, 2015
Publication date:
February 11, 2016
Inventors:
Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
October 6, 2016
Publication date:
January 26, 2017
Inventors:
Haibin Chen, Steven J. Collier, Jovana Nazor, Joly Sukumaran, Derek Smith, Jeffrey C. Moore, Gregory Hughes, Jacob Janey, Gjalt W. Huisman, Scott J. Novick, Nicholas J. Agard, Oscar Alvizo, Gregory A. Cope, Wan Lin Yeo, Stefanie Ng Minor
